Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Subscribe To Our Newsletter & Stay Updated